{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:09:33Z","timestamp":1790730573126,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.intimp.2015.07.007","type":"journal-article","created":{"date-parts":[[2015,7,25]],"date-time":"2015-07-25T00:45:13Z","timestamp":1437785113000},"page":"513-520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Quantitation of infliximab using clonotypic peptides and selective reaction monitoring by LC\u2013MS\/MS"],"prefix":"10.1016","volume":"28","author":[{"given":"Maria Alice V.","family":"Willrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Barnidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula M.","family":"Ladwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa R.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2015.07.007_bb0005","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.trsl.2014.09.006","article-title":"Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases","volume":"165","author":"Willrich","year":"2015","journal-title":"Transl. Res."},{"key":"10.1016\/j.intimp.2015.07.007_bb0010","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/clpt.2011.328","article-title":"Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms","volume":"91","author":"Ordas","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2015.07.007_bb0015","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/ibd.21904","article-title":"Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease","volume":"18","author":"Doherty","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.intimp.2015.07.007_bb0020","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.clinthera.2014.06.014","article-title":"Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study","volume":"36","author":"Wu","year":"2014","journal-title":"Clin. Ther."},{"key":"10.1016\/j.intimp.2015.07.007_bb0025","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2015.07.007_bb0030","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2015.07.007_bb0035","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cgh.2011.02.008","article-title":"Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease","volume":"9","author":"Jurgens","year":"2011","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2015.07.007_bb0040","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2010.9","article-title":"Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease","volume":"105","author":"Afif","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.intimp.2015.07.007_bb0045","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s10067-012-2040-2","article-title":"The effect of neutralizing antibodies on the sustainable efficacy of biologic therapies: what's in it for African and Middle Eastern rheumatologists","volume":"31","author":"Alawadhi","year":"2012","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2015.07.007_bb0050","first-page":"1118","article-title":"Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy","volume":"13","author":"Baert","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2015.07.007_bb0055","first-page":"B4616","article-title":"Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease","volume":"60","author":"Steenholdt","year":"2013","journal-title":"Dan Med. J."},{"key":"10.1016\/j.intimp.2015.07.007_bb0060","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/gut.2010.236869","article-title":"Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment","volume":"61","author":"Vande Casteele","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.intimp.2015.07.007_bb0065","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ajg.2013.12","article-title":"Antibody response to infliximab and its impact on pharmacokinetics can be transient","volume":"108","author":"Vande Casteele","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.intimp.2015.07.007_bb0070","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00216-010-4361-9","article-title":"An antibody-based biomarker discovery method by mass spectrometry sequencing of complementarity determining regions","volume":"399","author":"Dekker","year":"2011","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.intimp.2015.07.007_bb0075","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1021\/ac702115b","article-title":"Absolute quantification of monoclonal antibodies in biofluids by liquid chromatography\u2013tandem mass spectrometry","volume":"80","author":"Hagman","year":"2008","journal-title":"Anal. Chem."},{"key":"10.1016\/j.intimp.2015.07.007_bb0080","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1021\/ac800205s","article-title":"Towards absolute quantification of therapeutic monoclonal antibody in serum by LC\u2013MS\/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry","volume":"80","author":"Heudi","year":"2008","journal-title":"Anal. Chem."},{"key":"10.1016\/j.intimp.2015.07.007_bb0085","doi-asserted-by":"crossref","first-page":"9859","DOI":"10.1021\/ac402420v","article-title":"Fully validated LC\u2013MS\/MS assay for the simultaneous quantitation of coadministered therapeutic antibodies in cynomolgus monkey serum","volume":"85","author":"Jiang","year":"2013","journal-title":"Anal. Chem."},{"key":"10.1016\/j.intimp.2015.07.007_bb0090","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1021\/ac202792n","article-title":"General LC\u2013MS\/MS method approach to quantify therapeutic monoclonal antibodies using a common whole antibody internal standard with application to preclinical studies","volume":"84","author":"Li","year":"2012","journal-title":"Anal. Chem."},{"key":"10.1016\/j.intimp.2015.07.007_bb0095","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC\u2013MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal. Chem."},{"key":"10.1016\/j.intimp.2015.07.007_bb0100","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1373\/49.7.1041","article-title":"Ion suppression in mass spectrometry","volume":"49","author":"Annesley","year":"2003","journal-title":"Clin. Chem."},{"key":"10.1016\/j.intimp.2015.07.007_bb0105","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1373\/clinchem.2014.222208","article-title":"Quantification of serum IgG subclasses by use of subclass-specific tryptic peptides and liquid chromatography\u2013tandem mass spectrometry","volume":"60","author":"Ladwig","year":"2014","journal-title":"Clin. Chem."},{"key":"10.1016\/j.intimp.2015.07.007_bb0110","article-title":"The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease","author":"Vande Casteele","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.intimp.2015.07.007_bb0115","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1586\/egh.12.53","article-title":"Infliximab for the treatment of pediatric ulcerative colitis","volume":"6","author":"Bradley","year":"2012","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2015.07.007_bb0120","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ibd.21697","article-title":"Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies","volume":"18","author":"Reinisch","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.intimp.2015.07.007_bb0125","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","article-title":"Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease","volume":"4","author":"Maser","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2015.07.007_bb0130","doi-asserted-by":"crossref","first-page":"S-775","DOI":"10.1016\/S0016-5085(13)62866-8","article-title":"Tu1150 association of serum infliximab and antibodies to infliximab to long-term clinical outcome and mucosal healing in Crohn's disease","volume":"144","author":"Ben-Bassat","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2015.07.007_bb0135","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jim.2012.06.002","article-title":"Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum","volume":"382","author":"Wang","year":"2012","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.intimp.2015.07.007_bb0140","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1136\/annrheumdis-2013-203353","article-title":"The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab","volume":"72","author":"Plasencia","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2015.07.007_bb0145","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ajg.2012.363","article-title":"Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis","volume":"108","author":"Nanda","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.intimp.2015.07.007_bb0150","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00535-013-0829-7","article-title":"Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment","volume":"49","author":"Imaeda","year":"2014","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.intimp.2015.07.007_bb0155","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.2008.170","article-title":"Monoclonal antibody pharmacokinetics and pharmacodynamics","volume":"84","author":"Wang","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2015.07.007_bb0160","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.4155\/bio.10.64","article-title":"Therapeutic monoclonal antibody concentration monitoring: free or total?","volume":"2","author":"Kuang","year":"2010","journal-title":"Bioanalysis"},{"key":"10.1016\/j.intimp.2015.07.007_bb0165","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","article-title":"Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis","volume":"9","author":"van Schouwenburg","year":"2013","journal-title":"Nat. Rev. Rheumatol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576915300205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576915300205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:40:32Z","timestamp":1755650432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576915300205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S1567576915300205"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2015.07.007","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantitation of infliximab using clonotypic peptides and selective reaction monitoring by LC\u2013MS\/MS","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2015.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}